92 related articles for article (PubMed ID: 24284374)
1. Cancer stage and local immune response.
Murta EF
Immunol Lett; 2014; 159(1-2):79. PubMed ID: 24284374
[No Abstract] [Full Text] [Related]
2. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
Zhu S; Lin J; Qiao G; Xu Y; Zou H
Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
[TBL] [Abstract][Full Text] [Related]
3. CD8+ lymphocytes and apoptosis in typical and atypical medullary carcinomas of the breast.
Nurlaila I; Telisinghe PU; Ramasamy R
Immunol Lett; 2013; 156(1-2):123-6. PubMed ID: 24120509
[TBL] [Abstract][Full Text] [Related]
4. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.
Goff SL; Danforth DN
Clin Breast Cancer; 2021 Feb; 21(1):e63-e73. PubMed ID: 32893093
[TBL] [Abstract][Full Text] [Related]
5. The amount of surface HLA-I on T lymphocytes decreases in breast infiltrating ductal carcinoma patients.
Zhao S; Yang X; Lu N; Zhang Y; Li X; Li Y; Zhou Y; Wan F; Zou X
J Int Med Res; 2011; 39(2):508-13. PubMed ID: 21672354
[TBL] [Abstract][Full Text] [Related]
6. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
[TBL] [Abstract][Full Text] [Related]
8. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
[TBL] [Abstract][Full Text] [Related]
10. [The change of CD4+ CD25high CCR6+ regulatory T cells in breast cancer patients].
Xu L; Zhou Y; Xiao DM; Qin M; Luo JM; Tang XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 May; 41(3):415-9. PubMed ID: 20629311
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient.
Bernal-Estévez D; Sánchez R; Tejada RE; Parra-López C
BMC Cancer; 2016 Aug; 16():591. PubMed ID: 27484900
[TBL] [Abstract][Full Text] [Related]
12. Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Srivastava AN; Makker A; Goel MM
Indian J Cancer; 2013; 50(3):239-44. PubMed ID: 24061465
[TBL] [Abstract][Full Text] [Related]
13. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
[TBL] [Abstract][Full Text] [Related]
14. In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype.
Anz D; Eiber S; Scholz C; Endres S; Kirchner T; Bourquin C; Mayr D
Histopathology; 2011 Nov; 59(5):965-74. PubMed ID: 22092408
[TBL] [Abstract][Full Text] [Related]
15. Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
Chan MS; Chen SF; Felizola SJ; Wang L; Nemoto N; Tamaki K; Ishida T; Chow LW; Ohuchi N; Sasano H
Int J Biol Markers; 2014 Sep; 29(3):e193-203. PubMed ID: 24803281
[TBL] [Abstract][Full Text] [Related]
16. B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration.
Mugler KC; Singh M; Tringler B; Torkko KC; Liu W; Papkoff J; Shroyer KR
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):363-70. PubMed ID: 18091377
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
18. CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.
Ziai J; Gilbert HN; Foreman O; Eastham-Anderson J; Chu F; Huseni M; Kim JM
PLoS One; 2018; 13(1):e0190158. PubMed ID: 29320521
[TBL] [Abstract][Full Text] [Related]
19. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
Burugu S; Asleh-Aburaya K; Nielsen TO
Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
[TBL] [Abstract][Full Text] [Related]
20. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
